BofA lowered the firm’s price target on Tandem Diabetes to $18 from $33 and keeps an Underperform rating on the shares. While the firm contends that current medtech multiples have “likely discounted too much for GLP-1 concerns,” unless expectations change on GLP-1 weight-loss drugs, medtech likely will trade at some discount compared to recent history and the firm lowering some targets in the group to reflect this new discount as well as higher interest rates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNDM:
- Tandem Diabetes initiated with a Market Perform at Leerink
- Tandem Diabetes price target lowered to $23 from $31 at Citi
- Tandem Diabetes price target lowered to $45 from $47 at Jefferies
- DexCom price target lowered to $98 from $131 at Morgan Stanley
- Insulet price target lowered to $185 from $208 at Morgan Stanley